Novel Hybrids of Pyrazolidinedione and Benzothiazole as TZD Analogues. Rationale Design, Synthesis and In Vivo Anti-Diabetic Evaluation
Author:
- 26 August 2019
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Medicinal Chemistry
- Vol. 15 (6) , 624-633
Abstract
Background: The development of new classes of blood glucose–lowering medications has increased the number of treatment opportunities available for type 2 diabetes. Nevertheless, long term complicated treatments and side effects of available antidiabetic therapies have urged huge demands for effective affordable anti-diabetic agents that can lessen negative health consequences. In this sense, the exploration of alternative medicinal remedies associated with new significant antidiabetic efficiencies with minimized adverse effects is an active domain of research. Objective: The aim of this study was to synthesize a series of benzothiazole-pyrazolidinedione hybrids and evaluate their antidiabetic activity along with molecular docking and in silico analysis. Methods: The hybrids were synthesized by a multi-step synthesis and were further subjected for in vivo anti-hyperglycemic assessment on rat models of type II diabetes. Molecular modelling study was undertaken against peroxisome proliferator-activated receptor γ (PPARγ) to highlight possible key interactions. Results: Docking studies revealed that appropriate substituents on benzothiazole ring interacted favorably with the hydrophobic Ω-pocket of PPARγ binding site resulting in improving their antihyperglycemic activity. All the synthesized hybrids manifested promising anti-hyperglycemic potency. Excitingly, 5a, 5b and 5c were even more potent than the standard drug. Conclusion: The newly synthesized hybrids can be considered as a new class of antidiabetic agents and this study provided useful information on further optimization.Keywords
Funding Information
- Deanship of Scientific Research of King Faisal University (160004)
This publication has 38 references indexed in Scilit:
- Investigating structure–activity relationship and mechanism of action of antitubercular 1-(4-chlorophenyl)-4-(4-hydroxy-3-methoxy-5-nitrobenzylidene) pyrazolidine-3,5-dione [CD59]International Journal of Mycobacteriology, 2014
- Synthesis and antinociceptive activity of novel mannich base derivatives of some new fused 3,5-pyrazolidinedioneJournal of Advanced Pharmaceutical Technology & Research, 2014
- Design and synthesis of a series of α-benzyl phenylpropanoic acid-type peroxisome proliferator-activated receptor (PPAR) gamma partial agonists with improved aqueous solubilityBioorganic & Medicinal Chemistry, 2013
- Molecular modelling design, synthesis and cytotoxic evaluation of certain substituted 2-(3,4,5-triacetoxybenzoylamino)benzo[d]thiazole and 2-(galloylamino)benzo[d]thiazole derivatives having potential topoisomerase-I inhibitory activityJournal of Enzyme Inhibition and Medicinal Chemistry, 2012
- Benzothiazole-based N-(phenylsulfonyl)amides as a novel family of PPARα antagonistsBioorganic & Medicinal Chemistry Letters, 2011
- Design, synthesis and antidiabetic evaluation of oxazolone derivativesJournal of Chemical Sciences, 2011
- Identification of a PPARδ agonist with partial agonistic activity on PPARγBioorganic & Medicinal Chemistry Letters, 2009
- In vitro antitumor and antiviral activities of new benzothiazole and 1,3,4-oxadiazole-2-thione derivativesActa Pharmaceutica, 2008
- Phenylpropanoic acid derivatives bearing a benzothiazole ring as PPARδ-selective agonistsBioorganic & Medicinal Chemistry Letters, 2007
- Anticonvulsant Activity of 1-Alkyl-4-substituted 3,5-PyrazolidinedionesJournal of Pharmaceutical Sciences, 1974